PT671910E - Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma - Google Patents

Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma

Info

Publication number
PT671910E
PT671910E PT94903488T PT94903488T PT671910E PT 671910 E PT671910 E PT 671910E PT 94903488 T PT94903488 T PT 94903488T PT 94903488 T PT94903488 T PT 94903488T PT 671910 E PT671910 E PT 671910E
Authority
PT
Portugal
Prior art keywords
glaucoma
manufacture
treatment
medicinal product
adamantan
Prior art date
Application number
PT94903488T
Other languages
English (en)
Inventor
Stuart A Lipton
Evan B Dreyer
Original Assignee
Massachusetts Eye & Ear Infirm
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirm, Childrens Medical Center filed Critical Massachusetts Eye & Ear Infirm
Publication of PT671910E publication Critical patent/PT671910E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT94903488T 1992-12-04 1993-12-06 Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma PT671910E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/984,939 US5922773A (en) 1992-12-04 1992-12-04 Glaucoma treatment

Publications (1)

Publication Number Publication Date
PT671910E true PT671910E (pt) 2004-12-31

Family

ID=25531050

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94903488T PT671910E (pt) 1992-12-04 1993-12-06 Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma

Country Status (11)

Country Link
US (1) US5922773A (pt)
EP (1) EP0671910B1 (pt)
JP (2) JPH08506807A (pt)
KR (1) KR960700046A (pt)
AT (1) ATE275948T1 (pt)
AU (1) AU683634B2 (pt)
CA (1) CA2150933C (pt)
DE (1) DE69333626T2 (pt)
ES (1) ES2229213T3 (pt)
PT (1) PT671910E (pt)
WO (1) WO1994013275A1 (pt)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AU716577B2 (en) * 1994-07-06 2000-03-02 Sanofi-Aventis Use of polyamine antagonists for the treatment of glaucoma
JPH08231400A (ja) * 1995-02-24 1996-09-10 Rohto Pharmaceut Co Ltd イフェンプロジルを必須成分とする眼圧降下剤
JPH0967270A (ja) * 1995-08-31 1997-03-11 Res Dev Corp Of Japan 水晶体混濁の予防および治療法、並びにそのための薬 剤
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
WO1997023222A1 (en) 1995-12-21 1997-07-03 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
JP2000507205A (ja) * 1996-01-02 2000-06-13 シンテラボ 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用
AU2164797A (en) * 1996-03-14 1997-10-01 Synthelabo Polyamine site antagonist compositions
US5891871A (en) * 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
US6294544B1 (en) * 1996-04-26 2001-09-25 Fujisawa Pharmaceutical Co., Ltd. Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
ES2317650T3 (es) * 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
US6191126B1 (en) 1996-12-16 2001-02-20 Alcon Laboratories, Inc. Topical use of κ opioid agonists to treat ocular pain
EP0994709A4 (en) * 1997-06-30 2006-02-01 Allergan Inc CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY
US6159958A (en) * 1997-08-14 2000-12-12 The United States Of America As Represented By The Secretary Of The Army Treatment or prophylaxis of retinal pathology and spinal cord injury
AU1388999A (en) * 1997-12-16 1999-07-05 Alcon Laboratories, Inc. The use of nitric oxide generations for the treatment of dry eye disorders
JP2002503692A (ja) * 1998-02-23 2002-02-05 藤沢薬品工業株式会社 マクロライド系化合物の緑内障治療用途
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
WO2000007584A2 (en) * 1998-08-04 2000-02-17 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
WO2000038703A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
EP1169061A1 (en) * 1999-03-12 2002-01-09 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
WO2001010442A1 (fr) * 1999-08-09 2001-02-15 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la mort de cellules ganglionnaires de la retine
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
PT1227859E (pt) * 1999-11-12 2006-12-29 Alcon Inc Ligandos da neurofilina para o tratamento de patologias oculares
WO2001041756A2 (en) * 1999-12-02 2001-06-14 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
CA2398900A1 (en) * 2000-01-31 2001-08-09 Santen Pharmaceutical Co., Ltd. Therapeutic agents for opthalmopathy
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1974738A3 (en) * 2000-02-29 2008-12-17 Alcon, Inc. Diagnostics and therapeutics for glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
CN1680324A (zh) * 2000-05-30 2005-10-12 奥索-麦克尼尔药品公司 二氢吡啶软药及相关组合物和方法
DK2153819T3 (da) 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
CA2429480A1 (en) * 2000-11-22 2002-05-30 Tomiya Mano Ophthalmological preparations
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US6583152B2 (en) 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
JP2004532887A (ja) 2001-06-01 2004-10-28 アルコン，インコーポレイテッド 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
DK1392292T3 (da) 2001-06-01 2006-05-29 Alcon Inc Pyranoindazoler og deres anvendelse til behandling af glaukom
EP1392269A1 (en) 2001-06-01 2004-03-03 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
CA2488001C (en) 2002-06-06 2011-03-22 Merck Frosst Canada & Co. 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
US8557855B2 (en) 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043354A2 (en) 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006511556A (ja) 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
WO2004058238A1 (en) * 2002-12-23 2004-07-15 Alcon, Inc. Use of cathepsin k inhibitors for the treatment of glaucoma
WO2004069275A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation 眼科用剤
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
AU2004229283B2 (en) 2003-04-17 2009-02-05 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en) 2003-09-04 2009-02-24 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
NZ545401A (en) 2003-09-04 2008-10-31 Merck & Co Inc Ophthalmic compositions for treating ocular hypertension
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
WO2006020003A2 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20080033053A1 (en) * 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
BRPI0513862A (pt) * 2004-07-26 2008-05-20 Allergan Inc métodos de tratar condições oftálmicas
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2006122054A1 (en) * 2005-05-06 2006-11-16 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
CA2608476A1 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
JPWO2007097205A1 (ja) * 2006-02-02 2009-07-09 憲次 吉田 点眼剤
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
BRPI0816767B8 (pt) * 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
CN101801930B (zh) * 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP2010235597A (ja) * 2009-03-10 2010-10-21 Santen Pharmaceut Co Ltd ４，６−ジクロロ−１ｈ−インドール−２−カルボン酸誘導体又はその塩を有効成分として含有する視神経障害の予防又は治療剤
WO2010112615A1 (en) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Lysine derivatives functionalised with lipids
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CA2772876C (en) 2009-09-01 2019-01-15 Lz Therapeutics, Inc. Methods for extraction and purification of gangliosides
EP2473173A4 (en) * 2009-09-01 2013-03-06 Lz Therapeutics Inc TREATMENT OF GLAUCOMA AND OTHER RETINOPHATIES WITH GANGLIOSIDES
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
CN102883708A (zh) 2010-04-07 2013-01-16 阿勒根公司 用于眼用组合物的防腐剂联合
KR20130092957A (ko) 2010-04-07 2013-08-21 알러간, 인코포레이티드 안과용 처방용 보존제 조성물의 조합
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2602654B1 (en) * 2011-12-08 2023-04-19 Essilor International Ophthalmic filter
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102461134B1 (ko) 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
US10471070B2 (en) 2014-11-25 2019-11-12 Eyal Sheetrit Methods for delivering a bio-active agent or bio-active agents to an eye of a mammal
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4396625A (en) * 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
CA1319099C (en) * 1987-01-23 1993-06-15 James A. Nathanson Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US5070088A (en) * 1989-12-19 1991-12-03 E. R. Squibb & Sons, Inc. Pyranyl quinoline calcium channel blockers
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
CA2131101A1 (en) * 1992-05-13 1993-11-25 Louis Desantis Jr. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5435998A (en) * 1994-08-03 1995-07-25 Abelson; Mark B. Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents

Also Published As

Publication number Publication date
DE69333626T2 (de) 2005-02-10
DE69333626D1 (de) 2004-10-21
JP2006070039A (ja) 2006-03-16
EP0671910A1 (en) 1995-09-20
ATE275948T1 (de) 2004-10-15
KR960700046A (ko) 1996-01-19
JPH08506807A (ja) 1996-07-23
CA2150933A1 (en) 1994-06-23
ES2229213T3 (es) 2005-04-16
US5922773A (en) 1999-07-13
AU683634B2 (en) 1997-11-20
WO1994013275A1 (en) 1994-06-23
EP0671910B1 (en) 2004-09-15
EP0671910A4 (en) 1999-01-13
AU5741494A (en) 1994-07-04
CA2150933C (en) 2010-02-09

Similar Documents

Publication Publication Date Title
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
GEP20002146B (en) Therapeutic Peptide Derivatives
ES2077530A1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
NO952469D0 (no) Terapautisk kombinasjon som inneholder interferon
ES2040106T3 (es) Utilizacion de la acetil d-carnitina en el tratamiento terapeutico del glaucoma.
LV10924A (lv) Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
IL104006A0 (en) Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them
ES2160581T3 (es) Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano.
ATE102838T1 (de) Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel.
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
IE40860L (en) N- heterocyclylalkylbenzamides
SE9701161D0 (sv) New use I
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR910005858A (ko) 지방산 요법
JPS6483020A (en) Medicinal composition for preventing or treating aids
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
PT651654E (pt) Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa
KR950702433A (ko) Tcf-ii를 유효성분으로 하는 혈장 응고 정상화제
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
ATE293983T1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM